natgillin/translations-raw huggingface dataset:
Pojavile so se pri odmerkih, ki so bili vsaj 25-krat večji od odmerkov pri človeku, pri prejemanju kliničnega odmerka 75 mg na dan, in so bile posledica učinka na jetrne presnovne encime.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes.
Način uporabe za peroralno uporabo
Method of administration For oral use
Pri bolnikih, pri katerih ni bila opravljena angiografija, sta bila primarna opazovana dogodka smrt ali ponovni miokardni infarkt do 8. dneva oziroma do odpusta.
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge.
Če ima bolnik predviden kirurški poseg in antitrombotični učinek začasno ni zaželen, je potrebno zdravljenje
If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery.
ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97007-0
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97007-0
Preostale tablete zavrzite 30 dni po odprtju stekleničke.
Discard any remaining tablets 30 days after first opening of the bottle.
Bolezni sečil glomerulonefritis, zvišanje ravni kreatinina v krvi
Glomerulonephritis, blood creatinine increased
Preskušanji CLARINET in PICOLO so izvedli z uporabo pripravljene raztopine klopidogrela.
The CLARINET and the PICOLO trials were conducted using a constituted solution of clopidogrel.
Zaviralci glikoproteina IIb/IIIa: klopidogrel je potrebno uporabljati previdno pri bolnikih, ki se sočasno zdravijo z zaviralci glikoproteina IIb/IIIa (glejte poglavje 4.4).
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Cmax aktivnega presnovka je po enem 300-mg polnilnem odmerku klopidogrela dvakrat večja kot po štirih dneh uporabe vzdrževalnega odmerka 75 mg.
The Cmax of the active metabolite is twice as high following a single 300-mg clopidogrel loading dose as it is after four days of 75-mg maintenance dose.
Preostale tablete zavrzite 100 dni po odprtju stekleničke.
Discard any remaining tablets 100 days after first opening of the bottle.
filmsko obložena tableta
Film-coated tablet.
Farmakogenetika: Pri bolnikih, ki so slabi metabolizatorji CYP2C19, med uporabo priporočenih odmerkov klopidogrela nastane manj aktivnega presnovka klopidogrela in ima manjši učinek na delovanje trombocitov.
Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function.
s preiskavami krvi ali urina.
This may be detectable via blood or urine tests.
Pri zdravljenju tega stanja vam je zdravnik v zamašeno ali zoženo arterijo morda moral vstaviti stent (žično opornico), da bi žilo tako razširil in obnovil pretok krvi.
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow.
s pogostnostjo “neznani”.
* Information related to clopidogrel with frequency “not known”.
Jedro tablete laktoza monohidrat mikrokristalna celuloza hidroksipropil celuloza (E463) krospovidon (tip A) hidrogenirano ricinusovo olje natrijev lavrilsulfat
Lactose monohydrate Cellulose, microcrystalline Hydroxypropylcellulose (E463) Crospovidone (type A) Hydrogenated castor oil Sodium laurilsulfate
Tabelarični seznam neželenih učinkov
Tabulated list of adverse reactions
Incidenca klinično pomembnih krvavitev je bila podobna tisti, ki so jo opazili pri uporabi trombolitikov in heparina sočasno z acetilsalicilno kislino (glejte poglavje 4.8).
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8).
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
so po uporabi klopidogrela poročali zelo redko, včasih po kratki izpostavljenosti.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
Zdravnik vam bo moral predpisati tudi acetilsalicilno kislino (učinkovina proti bolečinam in za zniževanje zvišane telesne tempreature, kakor tudi za preprečevanje strjevanja krvi).
You should also be given acetylsalicylic acid (a substance used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor.
Teva Pharma B.V., Computerweg 10, 3542 DR Utrecht, Nizozemska
Computerweg 10, 3542 DR Utrecht, The Netherlands
Zdravilo Klopidogrel Teva Pharma B.V. morate jemati vse dokler vam ga vaš zdravnik predpisuje.
You should continue taking Clopidogrel Teva Pharma B.V. for as long as your doctor has told you to take it.
s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Q zobca, nizka do visoka raven tveganja, diabetes, potreba po revaskularizaciji, starost, spol, itd), so skladni z rezultati primarne analize.
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
Kaj je zdravilo Klopidogrel Teva Pharma B.V. in za kaj ga uporabljamo
What Clopidogrel Teva Pharma B.V. is and what it is used for
o če ste imeli pred kratkim kirurški poseg ali načrtujete kirurški poseg (vključno z o če imate kakršnokoli krvno motnjo, zaradi katere ste bolj nagnjeni k notranji krvavitvi o če imate kakršnokoli bolezen, zaradi katere ste bolj nagnjeni k notranji krvavitvi (npr.
For example: o If you have recently suffered from a serious injury o If you have recently undergone surgery or are due to have surgery (including dental surgery) o If you have any blood disorder which makes internal bleeding (bleeding inside your body) more likely o If you suffer from any other illness which makes internal bleeding more likely (e.g. stomach ulcers or wounds inside the eye)
resno obolenje, ki se imenuje trombotična trombocitopenična purpura (redka motnja strjevanja krvi, ki povzroči pojav številnih krvnih strdkov po celem telesu).
A serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body).
CYP2C19 je vključen tako v nastajanje aktivnega presnovka kot vmesnega presnovka, 2oksoklopidogrela.
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
in/ali hematološko reakcijo na enega od tienopiridinov, imajo lahko večje tveganje za pojav enake ali druge reakcije na drug tienopiridin.
Patients who had developed a previous allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
omeprazol, esomeprazol ali cimetidin, zdravila za zdravljenje težav z želodcem,
• Omeprazole, esomeprazole or cimetidine, medicines to treat upset stomach.
Preveliki odmerki klopidogrela lahko podaljšajo čas krvavitve in posledično povzročijo zaplete
Overdose following clopidogrel administration may lead to prolonged bleeding time and subsequent bleeding complications.
Koristi, ki so jih opazili pri uporabi klopidogrela, so bile neodvisne od drugih akutnih in dolgotrajnih srčnožilnih terapij (kot je heparin /nizkomolekularni heparin, antagonisti glikoproteina IIb/IIIa, učinkovine za zniževanje lipidov, blokatorji beta in zaviralci angiotenzinske konvertaze).
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
Pri bolnikih, ki so ostali na zdravljenju do pet dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6 % za klopidogrel v kombinaciji z acetilsalicilno kislino in 6,3 % za placebo v kombinaciji z acetilsalicilno kislino.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.
flukonazol, vorikonazol, ciprofloksacin ali klorampfenikol, zdravila za zdravljenje bakterijskih in glivičnih okužb,
• Fluconazole, voriconazole, ciprofloxacin, or chloramphenicol, medicines to treat bacterial and fungal infections.
Preostale tablete je potrebno odstraniti po preteku
Any remaining tablets should be discarded at the end of this period.
Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Risk Management Plan (RMP)
Sočasna uporaba z zdravilom Klopidogrel Teva Pharma B.V. ni priporočena.
Their use with Clopidogrel Teva Pharma B.V. is not recommended.
Pri bolnikih z akutnim koronarnim sindromom:
• Adult patients suffering from acute coronary syndrome:
Imetnik dovoljenja za promet z zdravilom in izdelovalci
Marketing Authorisation Holder and Manufacturer
peroralne koagulanse (zdravila, ki se uporabljajo za preprečevanje strjevanja krvi), kot je varfarin.
• Oral anticoagulants (oral medicines used to stop blood clotting) such as warfarin.
Zdravilo vsebuje tudi laktozo in hidrogenirano ricinusovo olje.
LIST OF EXCIPIENTS It also contains lactose and hydrogenated castor oil.
Krvavitev se lahko pojavi kot krvavitev iz želodca ali črevesja, kot odrgnine, hematomi (neobičajne krvavitve ali odrgnine pod kožo), krvavitev iz nosu, kri v urinu.
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleeds or blood in the urine.
Psihiatrične motnje halucinacije, zmedenost
Hallucinations, confusion
Zanjo je značilna trombocitopenija in mikroangiopatična hemolitična anemija, povezana ali z nevrološkimi spremembami, motnjo v delovanju ledvic ali povišano telesno temperaturo.
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever.
V primeru opaženih krvavitev je potrebno razmisliti o uvedbi ustreznega zdravljenja.
Appropriate therapy should be considered if bleedings are observed.
Bolniki so bili naključno razdeljeni v skupine, ki so prejemale klopidogrel 75 mg/dan ali acetilsalicilno kislino 325 mg/dan, spremljali so jih od 1 do 3 let.
Patients were randomised to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
takoj preučiti potrebo po določanju števila krvnih celic in/ali drugih ustreznih preiskav, kadar se v obdobju zdravljenja pojavijo klinični simptomi, ki nakazujejo krvavitev (glejte poglavje 4.8).
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).
Incidenca hujših primerov je bila podobna za klopidogrel in za acetilsalicilno kislino.
The incidence of severe cases was similar for clopidogrel and ASA.
in in vivo presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami in povzroči hidrolizo v neaktiven karboksilnokislinski derivat (85 % presnovkov v obtoku), druga pa z več encimi citokroma P450.
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Zaviralci protonske črpalke (PPI):
Proton Pump Inhibitors (PPI):
ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Clopidogrel has no or negligible influence on the ability to drive and use machines.
Madžarska
Hungary
Iz previdnosti naj sočasno ne bi uporabljali močnih ali srednje močnih zaviralcev CYP2C19 (za seznam zaviralcev CYP2C19 glejte poglavje 4.5; glejte tudi poglavje 5.2).
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
če imate hudo jetrno obolenje.
• If you have severe liver disease.
Klopidogrel je v primerjavi z acetilsalicilno kislino značilno zmanjšal incidenco novih ishemičnih dogodkov (sestavljen opazovani dogodek miokardni infarkt, ishemična kap in žilna smrt).
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA.
Encimi CYP450 morajo presnoviti klopidogrel, da nastane aktivni presnovek, ki zavira agregacijo trombocitov.
Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.
Aktivna patološka krvavitev kot je peptična razjeda ali
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.
nesteroidna protivnetna zdravila (za lajšanje bolečin zaradi vnetih sklepov ali mišic).
• Non-steroidal anti-inflammatory medicines (used to treat painful inflammatory conditions of the joints or muscles).
Bolnike je treba ocenite glede na anamnezo preobčutljivosti na tienopiridine (na primer na klopidogrel, tiklopidin in prasugrel), ker so poročali o navzkrižnih alergijah med tienopiridini (glejte poglavje 4.8).
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8).
Ta korist se je pokazala v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group].
Priporočeni odmerek acetilsalicilne kisline je bil od 75 do 100 mg na dan.
The recommended dose for ASA was 75 to 100 mg/day.
Okvarjeno delovanje ledvic Terapevtske izkušnje pri bolnikih z okvaro ledvic so omejene (glejte poglavje 4.4).
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4).
Bolezni imunskega sistema serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)*
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
Pri manjših urezninah ali poškodbah (npr. če se urežete pri britju), to navadno ni zaskrbljujoče.
For minor cuts and injuries (e.g. shaving cuts) you should not worry.
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišano vrednost srčnih encimov ali
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
V majhnem številu primerov so poročali tudi o očesnih krvavitvah, krvavitvah v glavi, pljučih ali sklepih.
In a small number of cases, bleeding in the eye, inside the head, the abdomen, the lung and the joints have also been reported.
simptomov in z njim nadaljevati vsaj štiri tedne.
Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks.
Sočasna uporaba heparina ni imela nobenega vpliva na zaviranje agregacije trombocitov, sproženo
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.
selektivne zaviralce privzema serotonina (vključno a ne omejeno na fluoksetin ali fluvoksamin),
• a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
Nadaljnja presnova vmesnega presnovka 2oksoklopidogrela povzroči nastanek aktivnega presnovka, ki je tiolski derivat klopidogrela.
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.
Zaradi previdnosti se je treba izogniti sočasni uporabi omeprazola ali esomeprazola (glejte poglavje 4.4).
As a precaution, concomitant use of omeprazole or esomeprozole should be discouraged (see section 4.4).
14x1 filmsko obložena tableta 28x1 filmsko obložena tableta 30x1 filmsko obložena tableta 50x1 filmsko obložena tableta 84x1 filmsko obložena tableta 90x1 filmsko obložena tableta 100x1 filmsko obložena tableta peroralna uporaba Pred uporabo preberite priloženo navodilo.
14x1 film-coated tablet 28x1 film-coated tablet 30x1 film-coated tablet 50x1 film-coated tablet 84x1 film-coated tablet 90x1 film-coated tablet 100x1 film-coated tablet
so preučevali v številnih študijah genotoksičnosti in vitro in in vivo, ki niso pokazale nobenega genotoksičnega učinka.
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity.
s hudo nevtropenijo trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Vrsta ovojnine in vsebina
PHARMACEUTICAL FORM AND CONTENTS
Zato je pri sočasni uporabi potrebna previdnost (glejte poglavje 4.4).
Therefore, concomitant use should be undertaken with caution (see section 4.4).
Posvetujte se tudi, če opazite katere koli neželene učinke, ki niso navedni v tem navodilu.
This includes any possible side effects not listed in this leaflet.
Iz previdnosti naj sočasno ne bi uporabljali močnih ali srednje močnih zaviralcev CYP2C19 (glejte poglavji 4.4 in 5.2).
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).
s CYP2C19, se razlikuje glede na raso/etnično pripadnost (glejte Farmakogenetika).
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics).
Antidot farmakološkemu delovanju klopidogrela ni znan.
No antidote to the pharmacological activity of clopidogrel has been found.
Kaj morate vedeti preden boste vzeli zdravilo Klopidogrel Teva Pharma B.V.
What you need to know before you take Clopidogrel Teva Pharma B.V.
Če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih
• You have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days
Opazovalne in klinične študije so dale razhajajoče se podatke o kliničnih posledicah tega farmakokinetičnega/farmakodinamskega medsebojnega delovanja, kar zadeva večje kardiovaskularne dogodke.
Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
even if their signs of illness are the same as yours.
Redno posodobljena poročila o varnosti zdravila (PSUR)
Periodic Safety Update Reports
V razvrstitvah pogostnosti so neželeni učinki navedeni po organskih sistemih in po padajoči resnosti.
Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness.
s klopidogrelom ali acetilsalicilno kislino, celokupna incidenca kakršnihkoli krvavitev 9,3 %.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
in strojev Malo verjetno je, da bi zdravilo Klopidogrel Teva Pharma B.V. vplivalo na vašo sposobnost upravljanja vozil
Driving and using machines Clopidogrel Teva Pharma B.V. is unlikely to affect your ability to drive or operate machinery.
Imetnik dovoljenja za promet z zdravilom:
Marketing Authorisation Holder:
Zato je potrebno pri teh bolnikih klopidogrel uporabljati previdno (glejte poglavje 4.2).
Therefore clopidogrel should be used with caution in these patients (see section 4.2).
Pri analizi po načelu začetnega namena zdravljenja so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala acetilsalicilno kislino, 1.020 dogodkov (zmanjšanje relativnega tveganja (zmanjšanje RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, pri dodatnih 10 [IZ: 0 do 20] bolnikih.
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
sočasna uporaba klopidogrela in peroralnih antikoagulansov ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (obolenje krvnih žil z izjemo
• You have hardening of the arteries and have recently suffered from a heart attack, a stroke or have a condition known as “peripheral arterial disease” (diseases of the blood vessels except those in the brain and heart).
To lahko pomeni, da je pri vas prisotna trombotična trombocitopenična purpura (redka motnja strjevanja krvi, ki lahko povzroči pojav številnih krvnih strdkov po celem telesu).
This could indicate that you are suffering from a serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body)
Zdravila Klopidogrel Teva Pharma B.V. ne smete prenehati jemati, ne da bi se o tem prej posvetovali z zdravnikom.
If you stop taking Clopidogrel Teva Pharma B.V. Do not stop taking Clopidogrel Teva Pharma B.V. without discussing it with your doctor first.
Drugi aleli, povezani z odsotno ali zmanjšano presnovo, so redkejši in vključujejo CYP2C19*4, *5, *6, *7 in *8. Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj.
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8.
takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih, če krvavitve postanejo resne ali se pojavijo krvavitve na neobičajnih mestih telesa (glejte poglavje 2 »Opozorila in previdnostni ukrepi«).
However, if you are in any doubt, bleeding becomes serious or you experience unexpected bleeding from unusual parts of your body you should contact your doctor straight away (see section 2 ‘Warnings and precautions').
Iz previdnostnih razlogov naj se z dojenjem med zdravljenjem z zdravilom Klopidogrel Teva Pharma B.V. ne nadaljuje.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Pharma B.V.
Bolnike je treba obvestiti, da je ob jemanju klopidogrela (samega ali v kombinaciji z acetilsalicilno kislino) čas, potreben za zaustavitev krvavitve, lahko daljši kot običajno, in da morajo
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.
Oddvojite posamezno enoto pretisnega omota od preostalega traku z nežnim
Separate one individual blister cell from the rest of the strip by gently tearing along the perforations around it.